Giorgia Guglielmi
Giorgia Guglielmi is a freelance science writer based in Basel, Switzerland. Specializing in life sciences, medicine, and the relationship between science and society, she has published numerous articles in outlets including Nature, Science, and Scientific American. She holds a PhD in biology from the European Molecular Biology Laboratory and a Master’s in Science Writing from the Massachusetts Institute of Technology. She has received recognition for her work, including the John Kendrew Award in 2020 and an ERC-funded FRONTIERS Media Fellowship in 2025. She has also led lectures and workshops on science communication at institutions such as Harvard University and the University of Zurich.
The findings of a recent study identified microbiota signatures that may allow clinicians to predict the outcomes of CAR-T immunotherapy.
Diet-induced changes in the gut microbiota confer protection against respiratory infections by regulating the development of key components of the immune system.
The findings of a recent study suggest that other gut microbes use liquid-liquid phase separation to colonize the gut, opening the way for new microbiota-based clinical applications.
The findings of a recent study suggest that estradiol-degrading bacteria could be therapeutic targets for treating depression in some women.
The findings of a recent study suggest that tilimycin-producing bacteria can cause genetic mutations in the colon and increase a person’s susceptibility to disease.
The findings of a new study shed light on a general mechanism by which gut bacteria may influence anti-cancer immune responses.
The findings of a new study suggest that mothers transmit bacteria to their infants through multiple routes — a process that ensures that babies receive essential microbes.
The findings of a new study suggest that providing at-risk populations with NOD2 ligands or probiotic bacteria that release high levels of NOD2-activating molecules may help to treat undernutrition.
The findings of a new study suggest that the microbial metabolite 3-IAA could help to treat PDAC.
The findings of a new study suggest that periodontal disease may contribute to rheumatoid arthritis by triggering specific immune responses.
